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indicate the need for additional high quality studies into patellar
taping and bracing effects on chronic knee pain.
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Purpose: Splints for base of the thumb osteoarthritis (OA) are
recommended in international guidelines but evidence for their
efﬁcacy in randomized trials are missing. The objective was to
assess the efﬁcacy and acceptability of splints for base of the
thumb OA.
Methods: Study design: Randomized controlled trial
Setting: Two tertiary care hospitals in France
Patients: 109 (94 women) patients with base of thumb car-
pometacarpal joint OA
Intervention: 56 patients received custom-made neoprene splint
and usual care (intervention) and 53 usual care (control)
Outcome measures: Primary outcome was pain assessed on
Visual Analog Scale (VAS, range 0-100) at 12 month follow-up.
Secondary outcome measures were pain at 1 and 6 month,
disability assessed by the Cochin Hand Function Scale (CHFS,
range 0-90) and pinch strength at 1, 6, and 12 month. Intention-
to-treat analyses were performed.
Results: Pain at 12 month follow-up had signiﬁcantly decreased
in both groups (from 45.5±20.0mm to 23.6±22.8mm in inter-
vention group, p= 0.0001, and from 47.7±20.0 to 39.2±24.2,
p=0.02 in control group), and an inter-group difference was ob-
served (-22.1±25.7 in intervention, and -8.8±25.2 in control
group, p=0.006). Pain inter-group difference was also observed
at 6 month but not at 1 month. Disability at 12 month was
not signiﬁcantly decreased in the intervention group (-2.0±12.9,
p=0.19) but was signiﬁcantly increased in the control group
(3.4±11.3, p=0.04), and an inter-group difference was observed
(p=0.03). Pinch strength was not modiﬁed in intervention and
control group. In the intervention group, 86% of patients wore
their splint at least 5 nights a week at 12 month and no adverse
effect was observed.
Conclusions: Our results suggest that splints are useful, safe,
and acceptable for patients with thumb carpometacarpal joint
OA.
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Purpose: The outcome of the goal study, an independent, long-
term, double-blind RCT in primary care patients with hip os-
teoarthritis (OA), was that glucosamine sulphate (GS) did not
have an effect on the symptoms and progression of hip OA over
the period of two years. In the study protocol subgroup analyses
were pre-speciﬁed to assess the effect of GS in subgroups of
patients.
Methods: In the GOAL study we randomly assigned 222 pa-
tients with hip OA to either 1500 mg of oral GS or a placebo
once daily for two years. Randomisation was stratiﬁed for severity
of radiographic OA (Kellgren and Lawrence (KL) = 1 vs. KL ≥
2) and for localisation (localised vs. generalised OA). For these
groups subgroup analyses were pre-speciﬁed. For additional ex-
ploratory analyses patients were also divided into groups based
on baseline level of pain (VAS ≤ 30 vs. VAS > 30).
General practitioners recruited prevalent hip OA patients. Pa-
tients were eligible when they met at least the clinical set of the
ACR criteria for hip OA. One of the exclusion criteria was being
on the waiting list for a total hip arthroplasty (THA).
Primary outcome measures were Western Ontario MacMas-
ter Universities (WOMAC) pain and function subscales over 24
months (0-100, 0 equals no pain), and joint space narrowing
(JSN) over 24 months. The WOMAC data was analysed using
mixed model analyses incorporating the scores from 3-monthly
questionnaires throughout the study, adjusted for possible con-
founders. The data for JSN was analysed using linear regression
analysis.
Results: We did not ﬁnd a signiﬁcant difference between GS
and placebo in any of the subgroups (Table 1). The outcomes for
WOMAC pain were adjusted for gender and BMI.
Table 1. Results per subgroup
Change from baseline (SD) Adjusted difference
(95% CI)Placebo group GS group
WOMAC pain
KL=1 (n = 117) -1.48 (26.0) -4.73 (19.3) -2.62 (-7.87, 2.63)
KL≥2 (n=105) 3.84 (26.8) 3.61 (21.8) 0.58 (-5.53, 6.69)
WOMAC function
KL=1 -1.04 (18.1) -2.62 (19.0) -3.09 (-7.45, 1.27)
KL≥2 5.58 (21.3) 1.94 (19.3) -0.58 (-6.05, 4.90)
JSN
KL=1 0.007 (0.29) -0.089 (0.36) -0.095 (-0.218, 0.029)
KL≥2 -0.136 (0.35) -0.102 (0.26) 0.066 (-0.082, 0.213)
WOMAC pain
localised (n=85) 1.76 (31.2) -1.10 (20.4) 0.99 (-5.89, 7.88)
generalised (n=137) 0.28 (22.8) -1.76 (21.1) -2.64 (-7.43, 2.14)
WOMAC function
localised 1.17 (23.0) -2.23 (20.2) -1.58 (-7.41, 4.24)
generalised 2.44 (17.3) 0.28 (18.3) -2.18 (-6.47, 2.10)
WOMAC pain
VAS ≤ 30 (n=122) 6.13 (23.7) 1.10 (21.0) -2.68 (-7.44, 2.08
VAS > 30 (n=100) -8.02 (28.5) -4.52 (20.1) -0.54 (-6.86, 5.78)
WOMAC function
VAS ≤ 30 4.81 (20.0) 1.09 (20.3) -3.14 (-7.40, 1.12)
VAS > 30 -3.10 (18.6) -3.13 (17.5) 1.56 (-7.27, 4.16)
In the subgroup of patients with KL = 1, the pain score of patients
on GS was better, while in the group with KL ≥ 2 this score was
better for the patients taking placebo. For WOMAC function the
estimates were in favour of placebo in both subgroups.
For subgroup analyses on the outcome for JSN, we found for
the group with KL = 1 that the patients taking placebo had less
JSN. In the group with KL ≥ 2 the patients in the GS group had
less JSN. None of the differences in the subgroups based on
radiographic severity were statistically signiﬁcant.
When we divided patients on the basis of localisation, we found
that in the group of patients with generalised OA, the patients
on GS scored better on pain and function than the patients
on placebo. Of the patients with localised OA, the ones taking
GS scored better on WOMAC function, while the patients taking
placebo scored better on WOMAC pain. The differences seen in
the subgroups based on localisation of OA were not statistically
signiﬁcant.
Finally we divided patients on the basis of their baseline VAS pain
score. In the group scoring lower than or equal to 30, the patients
taking GS had a better score on the WOMAC pain and function.
For the group with a baseline VAS of over 30, the ones on GS
scored better on WOMAC pain, but worse on WOMAC function.
Again, the differences described in the subgroups based on
baseline VAS score were not statistically signiﬁcant.
Conclusions: A once daily dose of 1500 mg of glucosamine
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sulphate during two years gave no difference in symptomatic
or radiographic outcomes in pre-speciﬁed subgroups of patients
with hip osteoarthritis. Also, exploratory analyses dividing pa-
tients on the basis of baseline pain-level, did not show an effect
of glucosamine sulphate.
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A COMPARISON OF VARIOUS PHYSIOTHERAPY
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Purpose: Few investigations include both subjective and ob-
jective measurements of the effectiveness of treatments for
osteoarthritis (OA) of the knee. Beneﬁcial interventions may
decrease the disability associated with osteoarthritis and the
need for more invasive treatments. The aim of this study was
to investigate the therapeutic effects of different physiotherapy
approaches on pain and functional status of patients with knee
OA. This study was conducted to design randomized, controlled
clinical trial at outpatient sports physiotherapy department of a
university hospital.
Methods: Eighty consecutive female patients, mean age (52.3
± 8.7) years with OA of one or both knees (Altman Grade II)
were sequentially divided into 4 random groups (GI to GIV). The
patients in group I received kinesiotherapy as required one time
15-min-long treatments per week for four weeks (n=20 women;
mean age: 51±8.3 years), group II received neuromuscular
electrical stimulation (NMES) for 30 minutes (n=20; mean age:
51.9±8.3 years), group III received functional training program
with proprioceptive ability by using Functional Squat System
(n=20; mean age: 51.2±6.4 years), and Group IV (n=20; mean
age: 53.3±9.1 years) acted as controls including home-based ex-
ercise program. Four groups were given a home-based exercise
programme and ice application aimed for reduce pain, improve
balance, and function. Treatment programmes were composed
of 5 days a week for 4 weeks/20 sessions. The changes of
muscle power of knee ﬂexion/extension were measured with a
ISOMED 2000 isokinetic dynamometer, Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC), Func-
tional Squat System-Proprioceptive Test, timed performance test
(Timed Up&Go) (TUG) and visual analogue scale for the intensity
of pain during activity, at rest and night were used to quantify the
variables before and after treatment.
Results: The results showed that the patients with knee OA in
each treated group had signiﬁcant improvement in pain reduc-
tion, disability reduction, and in walking speed after treatment
when compared with their initial status. No statistically signiﬁcant
differences were found between groups in pain reduction, walk-
ing speed and decrease of disability after treatment (p>0.05).
The greatest muscle strength gain in 600/s angular velocity
peak torques was found in the Group III (p<0.05). A difference
across time was observed for the pain and stiffness categories of
the WOMAC Osteoarthritis Index (p=0.04 and p=0.008, respec-
tively), with signiﬁcant differences between groups (p<0.05).
Improvement in WOMAC physical function scores was greater
in the group II and III than in the group IV at the end of treat-
ment; however, pain relief was observed at the ﬁrst month in
all groups.There was a correlation between proprioception ability
and pain intensity during activity in kinesiotape group (r=0.367;
p=0.04).
Conclusions: All treatment programmes are suggested in pa-
tients with OA with exercise knee pain, and for improving joint sta-
bility or walking endurance after treatmnet. The ﬁndings demon-
strate kinesiotherapy group, as it is utilized in clinical settings,
to be effective in the treatment of osteoarthritis of the knee.
These therapies used in combination may alleviate symptoms in
patients with OA.
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CLINICAL-BIOLOGICAL STUDY
E. Anitua1, M. Sánchez2, J. Azofra2, M. de la Fuente1,
M. Zalduendo1, J.J. Aguirre1, I. Andia1
1Biotechnology Institute, Vitoria, Spain; 2Unidad de Cirugía
Artroscópica, UCA, Vitoria, Spain
Purpose: Platelet-rich preparations represent a new biotech-
nology for the stimulation and enhancement of tissue healing.
The potential of an autologous preparation rich in growth fac-
tors (PRGF) to enhance tissue repair led to the idea of treating
degenerative joint conditions with autologous growth factors. Ob-
jectives: To investigate the efﬁcacy of PRGF treatment in patients
with knee OA and to explore whether intra-articular PRGF ad-
ministration could change selected investigative biomarker con-
centrations in the synovial ﬂuid.
Methods: This was a retrospective longitudinal study with no
controls. A cohort of 38 symptomatic knee OA patients pre-
senting with joint effusion was studied. Radiographic severity
was scored for Ahlbäck grading. Idiopathic and secondary post-
traumatic and mechanical OA, but not inﬂammatory OA, were
included. For the preparation of PRGF, peripheral blood was
collected into 9 cc tubes containing 3.8% (wt/vol) sodium citrate.
The tubes were centrifuged at 640g for 8 min, and the 2 cc
plasma fraction located just above the buffy coat was aspirated
and dispensed into an empty tube under vertical air ﬂow condi-
tions. Minutes prior to the injection, calcium chloride was added
at a ﬁnal concentration of 22.8 mM. PRGF treatment was ad-
ministered in series of three intra-articular injections at one-week
intervals. Investigative biomarkers (MMP-1, MMP-3, MMP-13,
TIMP-1, TIMP-2, HA, TGF-beta1, IGF-I, HGF, VEGF) relevant to
extracellular matrix destruction and cell signalling were analysed
in the synovial ﬂuid at baseline and two weeks after the start
of treatment. Factor analysis by the principal component (PCA)
method was carried out to reduce data to the most relevant set of
biomarkers. The pain subscale and global WOMAC index were
assessed at baseline and two months after treatment initiation. A
repeated measures ANCOVA model was used to compare differ-
ences in selected biomarkers and clinical parameters at baseline
and at follow-up. The variables included in the model were age,
gender, Ahlbäck grading and BMI.
Results: The total group comprised 38 patients with 46 knees
being examined. The mean age was 66 years (range: 44-87),
with 59% being female and an average BMI of 29.35 kg/m2
(range: 22-40). Principal component analysis showed that VEGF
and HGF loaded together in the ﬁrst component both at baseline
and two weeks after treatment initiation, accounting for 21.65%
and 23.60% of the variability, respectively. ANCOVA analyses
showed that VEGF and HGF changed with PRGF treatment
(p= 0.024 and 0.037, respectively). For the pain subscale and
overall WOMAC index, the changes between the baseline and
two month follow-up scores were statistically signiﬁcant (p=0.002
and p= 0.004, respectively). The observed success rates for
the pain subscale reached 32.6% (responders were deﬁned as
having a decrease in pain scale by a minimum of 40%) and
33.3% for the overall WOMAC (responders were deﬁned as
having WOMAC global index decreased by a minimum of 35%).
Conclusions: These results yield new perspectives on autolo-
gous treatments for joint diseases and may be pertinent as a
preliminary approach to select biomarkers for validation in PRGF
treatment monitoring.
